Some NPs are designed for the cytoplasmic delivery of antigens, which can be used to enhance anti-tumor responses of CD8+ cytotoxic T cells through cross-presentation of the antigen by major histocompatibility complex I (MHC-I). The gene discussed is CD8A; the disease is neoplasm.